Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

The integration of Vigil Neuroscience into French pharmaceutical giant Sanofi has been finalized. This strategic move, which concluded in late summer 2025, provides Sanofi with full control over Vigil’s promising neurology pipeline, with a particular focus on advancing a novel Alzheimer’s disease treatment candidate.

Transaction Details and Shareholder Terms

Sanofi secured the biotechnology firm through an all-cash transaction. The deal involved a payment of $8.00 per share, valuing the total acquisition at approximately $470 million. The company’s independence formally ended with its delisting from the Nasdaq in August 2025.

Key financial terms for former Vigil shareholders included:
* An upfront cash consideration of $8.00 per share upon deal closure.
* An additional Contingent Value Right (CVR) worth $2.00 per share.
* The CVR payment is contingent solely on the first commercial sale of the lead drug candidate, VG-3927.

Strategic Focus on VG-3927

The central asset driving this acquisition is VG-3927, an investigational oral treatment for Alzheimer’s disease. The drug candidate operates as a TREM2 agonist, representing a distinctive therapeutic approach. Sanofi is now preparing for Phase 2 clinical trials, following clearance from the U.S. Food and Drug Administration (FDA) in early 2025 to expand patient testing.

Should investors sell immediately? Or is it worth buying Vigil Neuroscience?

Initial Phase 1 data demonstrated a sufficient safety profile to warrant further clinical development. Sanofi anticipates that this molecule will substantially bolster its early-stage neurology portfolio.

Portfolio Rationalization and Excluded Assets

Not all of Vigil’s development programs were included in the takeover. Specifically, the antibody program VGL101 (iluzanebart) was retained by its original licensor, Amgen, prior to the completion of the Sanofi transaction. This decision followed the failure of a Phase 2 study for the asset in June 2025, where it did not meet its efficacy endpoints, leading to the discontinuation of its development for that specific indication.

This selective acquisition allows Sanofi to concentrate resources on the most valuable components of the pipeline it acquired.

For former Vigil investors, the future of VG-3927 remains the critical value driver. The potential $2.00 per share CVR payout is entirely dependent on the drug successfully navigating regulatory approval and achieving its first market sale.